4.Teva Pharmaceutical Industries ( TEVA) is an Israel-based drugmaker.

The numbers: Third-quarter net income inched up 3% to $649 million, but earnings per share fell 6% to 72 cents. Revenue increased 25% to $3.6 billion. Teva's gross margin decreased from 57% to 54%, but its operating margin expanded from 23% to 24%. A quick ratio of 0.9 indicates less-than-ideal liquidity. A debt-to-equity ratio of 0.3 reflects modest leverage.

The stock: Teva has risen 28% this year, beating the Dow Jones Industrial Average and S&P 500 Index. The stock trades at a price-to-earnings ratio of 57, a premium to the market and pharmaceutical peers. The shares have a 1.2% dividend yield.

If you liked this article you might like

Laureate Education's (LAUR) Underwhelming IPO Hasn't Scared Away Wall Street

It's Going to Take More Than Lax Regulation to Turn Around For-Profit Education Sector

Bank Fees, Payday Loans to Get Less Scrutiny From Trump's Consumer Watchdog

The Small Caps With Cash Portfolio Powers Ahead

The Small Caps With Cash Portfolio Powers Ahead

DeVry's Specialty Schools Shine as Regulatory Risk Hovers Over For-Profit Education